Mohammed T. Abou-Saleh

PRESENT AND FUTURE TREATMENTS OF AD 321‘‘superbly’’ on the Morris water maze, whereas untreated micedid not. The authors remarked that their data did not supportconcerns that attempts to remove b-amyloid from brain mightinadvertently cause wider dispersal and, therefore, moreextensive b-amyloid neurotoxic damage. A later populationbasedobservational study tested the hypothesis that the naturaloccurrence of antibodies to b-amyloid might reduce theincidence of dementia 102 . Although antibodies to b-amyloidcould be detected, no reduction in AD was found.CONCLUSIONThe future for AD therapy holds much promise. As the generalhealth of old people continues to improve and the incidence offunctional disabilities is reduced, so the achievement ofdementia prevention seems not only attainable but worthwhile.The huge collaborative international effort to understand themolecular pathology of AD and to design drugs to modifycritical steps is certain to bring great benefit to those at risk ofdementia.REFERENCES1. Porter R. The Greatest Benefit to Mankind: A Medical History ofHumanity from Antiquity to the Present. Fontana, 1997; 201–44.2. Whalley LJ. Early onset Alzheimer’s disease in Scotland: environmentaland familial factors. Br J Psychiat 2001; 178 (suppl.) s53–9.3. Rao VS, Cupples A, van Duijn CM et al. Evidence for major geneinheritance of Alzheimer’s disease in families of patients with andwithout apolipoprotein Ee4. Am J Hum Genet 1996; 59: 664–75.4. Cruts M, van Duyijn CM, Backhoven H et al. Estimation of thegenetic contribution of presenilin-1 and -2 mutations in apopulation-based study of presenile Alzheimer disease. Mol Genet1998; 7: 43–51.5. Liddell MB, Lovestone S, Owen MJ. Genetic risk of Alzheimer’sdisease: advising relatives. Br J Psychiat 2001; 178: 7–11.6. Christensen K, McGue M, Yashin A et al. Genetic and environmentalinfluences on functional abilities in Danish twins aged 75 years andolder. J Gerontol Ser A Biol Sci Med Sci 2000; 55: 446–52.7. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose ofapolipoprotein E type 4 allele and the risk of Alzheimer’s disease inlate onset families. Science 1993; 261: 921–3.8. Tallis R. Increasing longevity: medical, social and politicalimplications. J R Coll Physicians 1998; vii–ix.9. Grimley Evans J. Implications for health services. Phil Trans R SocLond Biol Sci 1997; 352: 1887–93.10. Rowe JW, Kahn RL. Successful aging. New York: Dell, 1999.11. Khaw K-T. Epidemiological aspects of Alzheimer’s disease. PhilTrans R Soc Lond B Biol Sci 1997; 352: 1829–35.12. Whalley LJ. The Ageing Brain. London: Weidenfeld and Nicolson,2001; 9–14.13. Harwood RH, Prince MJ, Mann AH et al. The prevalence ofdiagnoses, impairments, disabilities and handicaps in a population ofelderly people living in a defined geographical area: the Gospel OakProject. Age Ageing 1998; 27: 707–14.14. MRC CFAS. Profile of disability in elderly people: estimates from alongitudinal population study. Br Med J 1999; 318: 1108–11.15. Holmes J, House A. Psychiatric illness predicts poor outcome aftersurgery for hip fracture: a prospective cohort study. Psychol Med2000; 30: 921–9.16. Holmes J, House A. Psychiatric illness in hip fracture. Age Ageing2000; 29: 537–46.17. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind,placebo-controlled trial of donepezil in patients with Alzheimer’sdisease. Donepezil Study Group. Neurology 1998; 50: 136–45.18. Matthews H, Korbey J. Wilkinson D, Rowden J. Donepezil inAlzheimer’s disease—eighteen months results from SouthamptonMemory Clinic. Int J Geriat Psychiat (in press).19. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluatingthe efficacy and safety of ENA 713 (rivastigmine tartrate), a newacetylcholinesterase inhibitor, in patients with mild to moderatelysevere Alzheimer’s disease. Int J Geriat Psychopharmacol 1998; 1:55–65.20. Rosler M, Ananad R, Cicin-Sain A et al. Efficacy and safety ofrivastigmine in patients with Alzheimer’s disease: internationalrandomised controlled trial. Br Med J 1999; 318: 633–8.21. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension.The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261–8.22. Tariot PN, Solomon PR, Morris JC et al. A 5-month randomized,placebo-controlled trial of galantamine in AD. The GalantamineUSA-10 Study Group. Neurology 2000; 54: 2269–76.23. Winblat B, Wimo A. Assessing the societal impact ofacetylcholinesterase inhibitor therapies. Alzheim Dis Rel Dis 1999;suppl. 2: s9–19.24. Smith F, Gracon S, Knopman D et al. Tacrine and nursing homeplacement: application of the Cox proportional hazards model withtime-dependent covariates. Drug Inf J 1998; 32: 729–35.25. Schumock GT. Economic considerations in the treatment andmanagement of Alzheimer’s disease. Am J Health Syst Physicians1998; 55(suppl 2): s17–21.26. O’Brien BJ, Goeree R, Hux M et al. Economic evaluation ofdonepezil for the treatment of Alzheimer’s disease in Canada. JAmGeriat Soc 1999; 47: 570–8.27. McDonnell J, Redekpo WK, van der Roer et al. The cost of treatmentof Alzheimer’s disease in The Netherlands—a regression-basedsimulation model. Pharmacoeconomics 2001 19: 379–90.28. Nunomura A, Perry G, Pappolla MA et al. Neuronal oxidative stressprecedes amyloid-B deposition in Down syndrome. J NeuropatholExp Neurol 2000; 59: 1011–17.29. Nunomura A, Perry G, Pappolla MA et al. RNA oxidation is aprominent feature of vulnerable neurons in Alzheimer’s disease. JNeurosci 1999; 19: 1959–64.30. Vitek MP, Bhattacharya K, Glendening JM et al. Advanced glycationend products contribute to amyloidosis in Alzheimer disease. ProcNatl Acad Sci USA 1994; 91: 4766–70.31. Good PF, Werner P, Hsu A et al. Evidence of neuronal oxidativedamage in Alzheimer’s disease. Am J Pathol 1996; 149: 21–8.32. Sayre LM, Zelasko DA, Harris PLR et al. 4-Hydroxynonenal-derivedadvanced lipid peroxidation end products are increased inAlzheimer’s disease. J Neurochem 1997; 68: 2092–7.33. Smith MA, Harris PLR, Sayre LM, Perry G. Iron accumulation inAlzheimer disease is a source of redox-generated free radicals. ProcNatl Acad Sci USA 1997; 94: 9866–8.34. Smith MA, Harris PLR, Sayre LM et al. Widespread peroxynitritemediateddamage in Alzheimer’s disease. J Neurosci 1997; 17: 2653–7.35. Colton CA, Gilbert DI. Production of superoxide anions by a CNSmacrophage, the microglia. Fed Exp Biol Sci (letter) 1987, 284–8.36. Yan S-D, Chen X, Schmidt A-M et al. Glycated tau protein inAlzheimer’s disease: a mechanism for induction of oxidant stress.Proc Natl Acad Sci USA 1994; 91: 7787–91.37. El Khoury J, Hickman SE, Thomas CA et al. Scavenger receptormediated adhesion of microglia to -amyloid fibrils. Nature 1996; 382:716–19.38. McGeer P, Rogers J. Anti-inflammatory agents as a therapeuticapproach to Alzheimer’s disease. Neurology 1992; 42: 447–9.39. Rogers J, Kirby LC, Hempelman SR et al. Clinical trial ofindomethacin in Alzheimer’s disease. Neurology 1993; 43: 1609–11.40. Breitner JCS, Gau BA, Welsh KA et al. Inverse association of antiinflammatorytreatments and Alzheimer’s disease: initial results of aco-twin control study. Neurology 1994; 44: 227–32.41. Rich JB, Rasmusson DX, Folstein MF et al. Nonsteroidalantiinflammatory drugs in Alzheimer’s disease. Neurology 1995; 45: 51–5.42. Smallhieser NR, Swanson DR. Indomethacin and Alzheimer’sdisease. Neurology 1996; 46: 583.43. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer’s diseaseand duration of NSAID use. Neurology 1997; 48: 626–31.44. Munch G, Taneli Y, Schraven E et al. The cognition enhancing drugtenilsetam is an inhibitor of protein crosslinking by advancedglycation. J Neur Transm 1994; 193–208.45. Munch G, Mayer S, Michaelis J et al. Influence of advanced glycationend products and ACE-inhibitors on nucleation dependent